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Background: Using data from a large phase III study of previously treated advanced non-small-cell lung cancer
(NSCLC) that showed similar efficacy for pemetrexed and docetaxel, this retrospective analysis evaluates the impact of
first-line chemotherapy on the outcome of second-line chemotherapy.
Patients and methods: In all, 571 patients with advanced NSCLC were randomly assigned to receive pemetrexed
500 mg/m2 or docetaxel 75 mg/m2 on day 1 of a 21-day cycle. Comparisons were made based on type of first-line
therapy [gemcitabine + platinum (GP), taxane + platinum (TP), or other therapies (OT)], response to initial therapy, time
since initial therapy, and clinical characteristics. The two second-line treatment groups were pooled for this analysis
due to similar efficacy and were assumed to have no interaction with the first-line therapies.
Results: Baseline characteristics were generally balanced. By multivariate analysis, gender, stage at diagnosis,
performance status (PS), and best response to first-line therapy significantly influenced overall survival (OS). Additional
factors by univariate analysis, histology, and time elapsed from first- to second-line therapy significantly influenced OS.
Conclusions: Future trials in the second-line setting should stratify patients by gender, stage at diagnosis, PS, and
best response to first-line therapy.
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introduction
Current American Society of Clinical Oncology (ASCO) and
National Comprehensive Cancer Network (NCCN) guidelines
recommend treatment of advanced non-small-cell lung cancer
(NSCLC) with platinum-based doublet combination
chemotherapy in the first-line setting and with nonplatinum-
based doublets as a reasonable alternative [1, 2]. These
recommendations are based on multiple randomized clinical
trials comparing various platinum-based doublets and
nonplatinum-based doublets including trials of the Southwest
Oncology Group and Eastern Cooperative Oncology Group
(ECOG) [3–9].
Preliminary results of a randomized phase II/III trial, ECOG
4599 were reported at ASCO 2005, evaluating the role of
bevacizumab (B) in addition to carboplatin and paclitaxel (PC)
in selected NSCLC patients. The addition of B to PC is
significantly superior in response (27% versus 10%, P < 0.0001),
progression-free survival (6.4 months versus 4.5 months,
P < 0.0001), and median survival (12.5 months versus 10.2
months, P = 0.0075) compared with the PC arm alone [10].
ASCO and NCCN guidelines recommend docetaxel,
pemetrexed, or erlotinib in the second-line setting. These
recommendations were based on randomized clinical trials
comparing these agents with best supportive care or placebo
plus best supportive care, respectively, in two randomized trials.
Shepherd et al. [11] compared docetaxel 75–100 mg/m2 with
best supportive care in an international study of 204 patients.
Median survival was 7.5 months versus 4.6 months that
translated into a superior 1-year survival rate of 37% versus
12%, P = 0.003, favoring docetaxel 75 mg/m2 over the control
arm. In another study of 373 patients, Fossella et al. [12]
compared docetaxel 75 or 100 mg/m2 with the control group of
either vinorelbine or ifosfamide. Subjects treated with docetaxel
had significantly longer time to progression (TTP) versus the
control group (P = 0.046). One-year survival was 32% for
docetaxel 75 mg/m2 versus 19% for vinorelbine or ifosfamide
(P = 0.025); however, the overall survival (OS) time was not
significantly different.
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A large randomized phase III comparison trial of pemetrexed
to docetaxel showed similar survival with median survival
times (MSTs) of 8.3 and 7.9 months, respectively [hazard ratio
(HR), 0.99; 95% confidence interval (CI), 0.82 to 1.2] [13].
Objective and subjective response rates and TTP were also
similar in the two arms. There were, however, significantly
more grade 3/4 hematologic toxicity, febrile neutropenia, and
drug-related hospitalizations on the docetaxel arm. On the
basis of this trial and other trial data supporting pemetrexed
results, the Food and Drug Administration (FDA) approved
the use of pemetrexed in the second-line setting.
The BR.21 trial [14] was a large phase III trial of 731 patients
who underwent 2 : 1 randomization to 150 mg oral erlotinib
daily or placebo after failing one or two prior chemotherapy
regimens. The erlotinib arm had a response rate of 8.9% versus
<1% on the placebo arm (P < 0.001), and an OS rate of 6.7
months versus 4.7 months, respectively (HR 0.70; P < 0.001).
On the basis of these data, docetaxel and pemetrexed are
FDA-approved in the second-line setting, and erlotinib is
approved in the second- or third-line setting.
On the basis of the aforementioned data, docetaxel and
pemetrexed have received regulatory approval worldwide in the
second-line setting, and erlotinib is approved for both the
second- and third-line setting. With at least three agents
approved for advanced NSCLC patients in the second-line
setting and the development of new agents, it is probable that
many randomized phase III trials will be comparing agents in
the second-line setting. Optimal study design will require
appropriate stratification on the basis of established prognostic
factors. Factors that were prospectively stratified for in the
randomized trial comparing pemetrexed with docetaxel in the
second-line setting included the following: performance status
(PS) at start of second-line therapy, prior platinum or paclitaxel
use, number of prior chemotherapy regimens, time since last
chemotherapy, best response to last chemotherapy, stage at
diagnosis, baseline plasma homocysteine level, and center. In
this retrospective analysis of the randomized trial, we evaluate
age, gender, stage, PS at start of second-line therapy, type of
first-line chemotherapy, response to first-line chemotherapy,
and time elapsed from first- to second-line chemotherapy
on survival outcome in the second-line setting [13]. Baseline
values for lactate dehydrogenase, percent change in weight
loss (<10%), and smoking history were not available.
patients and methods
The major efficacy and toxicity findings from the phase III trial comparing
pemetrexed (Alimta, Eli Lilly and Company, Indianapolis, IN, USA) with
Table 1. Patient and disease characteristics for three groups (GP, TP, and OT)
Total (n = 571) GP (n = 182) TP (n = 113) OT (n = 276)
Median age (range) 58 (22–87) 57 (22–79) 58 (40–87) 59 (30–81) P = 0.177a
Gender P < 0.001b
Female (%) 160 (28%) 53 (29%) 46 (41%) 61 (22%)
Male (%) 411 (72%) 129 (71%) 67 (59%) 215 (78%)
Stage III (%) 144 (25%) 33 (18%) 26 (23%) 85 (31%) P = 0.008b
Stage IV (%) 427 (75%) 149 (82%) 87 (77%) 191 (69%)
Histology P = 0.047b
Adeno (%) 296 (52%) 97 (53%) 71 (63%) 128 (46%)
Squamous (%) 171 (30%) 56 (31%) 25 (22%) 90 (33%)
Other (%) 104 (18%) 29 (16%) 17 (15%) 58 (21%)
Performance status (n = 538) (n = 174) (n = 106) (n = 258) P = 0.849b
ECOG PS 0 (%) 100 (19%) 35 (20%) 19 (18%) 46 (18%)
ECOG PS 1 (%) 374 (70%) 122 (70%) 74 (70%) 178 (69%)
ECOG PS 2 (%) 64 (12%) 17 (10%) 13 (12%) 34 (13%)
Best response to first-line therapy (n = 545) (n = 179) (n = 113) (n = 253) P = 0.714a
CR 16 (3%) 7 (4%) 1 (1%) 8 (3%)
PR 190 (35%) 66 (37%) 38 (34%) 86 (34%)
SD 199 (37%) 63 (35%) 46 (41%) 90 (36%)
PD 140 (26%) 43 (24%) 28 (25%) 69 (27%)
Time elapsed to second-line therapy (n = 563) (n = 179) (n = 113) (n = 271) P = 0.003a
£3 months 277 (49%) 87 (49%) 61 (54%) 129 (48%)
3–6 months 117 (21%) 50 (28%) 24 (21%) 43 (16%)
‡6 months 169 (30%) 42 (23%) 28 (25%) 99 (37%)
Number of metastatic sites (n = 479) (n = 146) (n = 90) (n = 243) P = 0.422b
1 75 (16%) 22 (15%) 9 (10%) 44 (18%)
2–3 251 (52%) 74 (51%) 50 (56%) 127 (52%)
>4 154 (32%) 50 (34%) 31 (34%) 73 (30%)
aP = analysis of variance.
bP = chi-square analysis.
GP, gemcitabine + platinum; TP, taxane + platinum; OT, other therapies; ECOG PS, Eastern Cooperative Oncology Group performance status;
CR, complete response; PR, partial response; SD, stable disease; and PD, progressive disease.
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docetaxel (Taxotere, Sanofi-Aventis, Bridgewater, NJ, USA) in the second-
line setting were previously published [13]. Briefly, all patients had
confirmed stage III or IV NSCLC; had received no more than one prior
chemotherapy regimen for the treatment of advanced disease; had an ECOG
PS of zero to two; were ‡18 years of age, with measurable or evaluable
disease; and had adequate bone marrow, hepatic, and renal function.
Exclusion criteria included the following: prior docetaxel or pemetrexed
treatment, significant weight loss (‡10% body weight during the previous 6
weeks), ‡ grade 3 peripheral neuropathy, symptomatic or uncontrolled
brain metastases, uncontrolled pleural effusions, or an inability to interrupt
nonsteroidal anti-inflammatory drugs. All patients provided written
informed consent before treatment. The protocol was approved by each
institution’s ethical review board.
From March 2001 through February 2002, 571 patients were randomly
assigned to receive either docetaxel 75 mg/m2 (n = 288) or pemetrexed
500 mg/m2 (n = 283) every 3 weeks. All 571 patients were assessable for
survival and TTP analyses; 538 patients qualified for objective tumor
response evaluation. Time elapsed since first-line therapy was available
on 563 patients and PS at start of second-line therapy was available on
538 patients. Best response rate to first-line treatment was available on
545 patients and used the reported data collected at study entry and did not
undergo independent radiologic confirmation.
statistical analysis
The retrospective statistical analysis compared the survival data for all
patients combined and each of the three first-line treatment groups from
the randomized, phase III, advanced NSCLC study based on first-line
therapy received: gemcitabine + platinum (GP) (n = 182), taxane +
platinum (TP) (n = 113), and other therapies (OT) (n = 276). The OT
group consisted of vinorelbine + platinum (35%), etoposide + platinum
(19%), gemcitabine + vinorelbine (11%), and other regimens (35%).
In the phase III study, the efficacy measures of pemetrexed and docetaxel
were similar. There was no interaction between the first-line therapies and
the second-line therapy. Therefore, the outcome data for these two
treatment groups were pooled for this analysis. Unless otherwise stated, all
tests of hypotheses were conducted at the a = 0.05 level, with a 95% CI.
Cox proportional hazards model was used for the comparison of survival
and TTP (data not shown) among the first-line therapies in baseline
characteristics, subgroups when applicable (e.g. age and gender), and
treatment and subgroup by treatment interaction. Both unadjusted and
adjusted comparisons for the predictors were analyzed for survival.
Kaplan–Meier estimates were used to assess medians and percentiles.
Comparison of the tumor response rates among the first-line therapies
Table 2. Survival univariate and multivariate analyses
Characteristics Median
survival
Univariate
P value
Multivariate
P value
Age
<70 7.9 0.809 NA
‡70 8.8
Gender
Male 7.2 0.001 0.03
Female 9.4
Stage
III 9.5 0.036 0.012
IV 7.8
Histology
Adenocarcinoma 9.1 0.004 0.054
Squamous cell carcinoma 6.5
Other/mixed 7.8
Performance status
0 12.7 <0.001 <0.001
1 8.3
2 2.6
Best response to first-line therapy
CR/PR 15.8 <0.001 <0.001
SD 10.5
PD 4.6
Time elapsed to second-line therapy
£3 months 6.9 0.001 0.183
3–6 months 9.2
‡6 months 9.3
First-line regimen
GP 9.1 0.626 NA
TP 7.4
OT 7.8
CR/PR, complete response/partial response; SD, stable disease; PD,
progressive disease; GP, gemcitabine + platinum; TP, taxane + platinum;
OT, other therapies; and NA, not available.
Table 3. Summary of overall survival time subgroup analyses
Subgroup GP
MST
TP
MST
OT
MST
Treatment
P value
Subgroup by
treatment
interaction
P value
Gender
Female 9.9 7.9 9.6 0.159 0.535
Male 8.4 5.8 7.2 0.620
Agea
<70 9.1 7.0 7.5 NA NA
‡70 8.8 9.1 8.8
Stage
III 13.0 8.0 9.0 0.137 0.346
IV 8.7 7.4 6.7 0.748
Histology
Adenocarcinoma 9.5 7.8 8.8 0.164 0.713
Squamous cell
carcinoma
7.65 7.4 6.0 0.701
Other/mixed 8.8 5.8 7.9 0.984
Performance status
0 10.1 10.5 13.7 0.128 0.275
1 9.1 7.8 7.7 0.670
2 3.7 2.0 2.6 0.116
Best overall response
CR/PR 18.5 12.4 13.3 0.679 0.714
SD 10.2 9.9 10.8 0.765
PD 4.2 5.2 4.8 0.579
Time to first line
£3 months 8.3 6.2 6.4 0.570 0.925
3–6 months 9.2 7.5 7.8 0.740
‡6 months 9.8 8.4 9.3 0.374
aAge was not further examined for interaction in a subgroup analysis
since the factor was not significantly associated with increased survival
in the Cox proportional hazards model.
GP, gemcitabine + platinum; TP, taxane + platinum; OT, other therapies;
MST, median survival time in months; NA, not available;
CR/PR, complete response/partial response; SD, stable disease; and
PD, progressive disease.
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was made using the Fisher’s exact test with 95% CI calculated using the
method of Leemis and Trivedi [15].
results
Baseline characteristics are shown in Table 1. Median survival
by baseline characteristics with univariate and multivariate
analysis is shown in Table 2. Median survival by baseline
characteristics and treatment group is shown in Table 3.
age
The median age was 58 (range 22–87) in the entire patient
population and 57 (range 22–79), 58 (range 40–87), 59 (range
30–81) in the GP, TP, and OT groups, respectively (P = 0.177)
(Table 1). Age was not a significant prognostic factor [16].
Patients who were elderly (‡70 years old) had a median survival
of 8.8 months compared with 7.9 months for those <70 years
(P = 0.809) (Table 2).
gender
There were 411 (72%) males and 160 (28%) females in the
entire group. In the GP, TP, and OT groups, there were 71%,
59%, 78% males, respectively (P < 0.001) (Table 1). TP had
significantly more women than the other two groups. Gender
was a significant prognostic factor as the median survival
for females was 9.4 months versus 7.2 months for males
(P = 0.001) (Table 2).
stage at diagnosis
There were 144 (25%) with stage III disease and 427 (75%)
with stage IV disease at diagnosis for the entire population.
In the GP, TP, and OT groups, there were 82%, 77%, and
69% with stage IV disease at diagnosis, respectively (P = 0.008)
(Table 1). Stage at diagnosis was also a significant prognostic
factor as the median survival for stage III disease at diagnosis
was 9.5 months compared with 7.8 months for stage IV disease
(P = 0.036) (Table 2).
histology
For the entire population, 296 (52%) had adenocarcinoma,
171 (30%) had squamous cell carcinoma, and 104 (18%)
had other or mixed histology. In GP, TP, and OT groups,
53%, 63%, and 46% had adenocarcinomas, respectively
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Figure 1. Survival by performance status at the start of second-line therapy. (A) Entire population, (B) gemcitabine + platinum, (C) taxane + platinum,
and (D) other therapies.
original article Annals of Oncology
456 | Weiss et al. Volume 18 |No. 3 |March 2007
(P = 0.047) (Table 1). TP had more adenocarcinoma
histology than the other two groups. Histology was
a significant prognostic factor as the median survival for
patients with adenocarcinoma was 9.1 months, 6.5 months
for squamous cell carcinoma, and 7.8 months for other or
mixed histology (P = 0.004) (Table 2).
PS at start of second-line treatment
Of the 538 patients evaluated for PS, 100 (19%) had ECOG PS of
zero, 374 (70%) had ECOG PS of one, and 64 (12%) had ECOG
PS of two. [Unknown was not included in analyses (n = 33)].
For GP, TP, and OT, the percentages were similar (P = 0.849)
(Table 1). PS was a significant prognostic factor. For all patients,
median survival was 12.7 months for ECOG PS of zero, 8.3
months for ECOG PS of one, and 2.6 months for ECOG PS of
two (P < 0.001) (Table 2). Figures 1A–D show OS based on
PS for the entire population, GP, TP, and OT, respectively.
best overall response to first-line treatment
For the whole study population, best responses to first-line
therapy were 16 (3%) complete response (CR), 190 (35%)
partial response (PR), 199 (37%) stable disease (SD), and
140 (26%) progressive disease (PD). The objective response
rate was 41% for GP, 35% for TP, and 37% for OT (P = 0.714)
(Table 1). The disease control rate (CR/PR + SD) was 76%
for GP, 76% for TP, and 72% for OT. Initial response to
chemotherapy was a significant prognostic factor. For all
patients, median survival was 15.8 months for CR/PR, 10.5
months for SD, and 4.6 months for PD (P < 0.001) (Table 2).
Figures 2A–D show OS based on best response to first-line
therapy for the entire population, GP, TP, and OT, respectively.
time elapsed from first- to second-line therapy
Patients were analyzed on the basis of time elapsed from first- to
second-line therapy and grouped as £3 months, 3–6 months,
and ‡6 months. Time elapse to initiation of second-line therapy
for the study population was 277 (49%) £3 months, 117 (21%)
3–6 months, and 169 (30%) ‡6 months elapse to initiation
of second-line therapy. Time since initial chemotherapy was
a significant prognostic factor as median survival was
6.9 months, 9.2 months, and 9.3 months for £3 months,
3–6 months, and ‡6 months groups, respectively (P = 0.001)
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Figure 2. Survival by best overall response to first-line therapy. (A) Entire population, (B) gemcitabine + platinum, (C) taxane + platinum, and
(D) other therapies.
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(Table 2). Figures 3A–D show OS based on time elapsed from
first- to second-line therapy for the entire population, GP, TP,
and OT, respectively.
first-line regimen
Of the 571 patients randomly assigned and treated in the
second-line study, 182 patients received GP, 113 received TP,
and 276 received OT for first-line treatment. Patients treated
with first-line GP had a numerically superior MST (9.1 months)
relative to TP (7.4 months) or OT (7.8 months), but these
differences failed to reach statistical significance (P = 0.626)
(Table 2 and Figure 4).
Thus, by univariate analyses the following characteristics
significantly influenced OS as follows: gender, stage at diagnosis,
histology, PS, best overall response to first-line therapy, and
time elapsed from first- to second-line therapy (Table 2). By
multivariate analysis, the following characteristics significantly
influenced OS as follows: gender, stage at diagnosis, PS, and best
overall response to first-line therapy (Table 2).
In Table 3, the analysis of the subgroups within the baseline
characteristics by treatment (GP, TP, or OT) did not
demonstrate significant interaction. For each subgroup,
there were no significant median OS differences by
treatment group.
discussion
In this randomized trial comparing pemetrexed with docetaxel
in the second-line setting of advanced NSCLC, we found that
the following variables were associated with survival outcome:
gender, histology, stage at diagnosis, PS at start of second-line
therapy, type of initial therapy, best response to initial therapy,
and time since initial therapy. Of these, type of initial therapy
was not statistically significant in univariate analysis, while the
following factors were statistically significant by multivariate
analyses: gender, stage at diagnosis, PS at start of second-line
therapy, and best response to initial therapy. Thus, these four
factors should be used as stratification factors in future
randomized trials. It should be noted that interpretation of best
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Figure 3. Survival by time elapsed from first- to second-line therapy. (A) Entire population, (B) gemcitabine + platinum, (C) taxane + platinum,
and (D) other therapies.
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response to first-line therapy by imaging was not confirmed
in a standardized fashion. It is not surprising that status and
gender have a significant impact on survival [17–18]. Appetite
and weight loss have been reported as prognostic factors in the
first-line setting [17], however, this data is not available for our
analyses.
Other factors that should be documented when enrolling
patients on trials are tumor histology and time elapsed from
first- to second-line therapy. In the phase III study, the time
elapse groups were divided into <3 or ‡3 months. In this
analysis, the time elapse groups were further divided (£3, 3–6,
and ‡6 months). While there was significant survival
improvement with longer time elapse by univariate analysis, this
trend did not persist in the multivariate analysis. Smoking
history in pack-years was not available in our data, but would be
of interest when enrolling patients into trials beyond first-line
therapy to see if this is an independent prognostic factor.
This retrospective analysis is the first to show the potential
influence of first-line chemotherapy on the outcome of second-
line cytotoxic chemotherapy. First-line therapy with GP has
a numerically higher survival time compared with TP or OT.
This outcome was similar regardless of best response to first-line
treatment or length of time since discontinuing therapy.
To our knowledge, the effect of first-line chemotherapy on
outcomes using targeted chemotherapy in advanced NSCLC has
not been previously published. As more randomized trials are
designed to answer treatment options in second-line therapy
and beyond, conducting subset and retrospective analyses will
help guide future study and hypotheses. Three additional areas
that may be worth pursuing in data collection would be quality-
of-life (QoL) improvement, and toxicity patients experienced
within the first-line setting prior to enrollment in a second-line
or beyond chemotherapy trial. Larger numbers of patients
would have to be pooled to look for trends, but results of
analysis might shed light on toxicity-prone individuals or
profiles of patients most likely to benefit by QoL improvement
despite poor prognostic factors or PS.
In conclusion, future trials in the second-line setting should
stratify patients by gender, stage at diagnosis, PS at start of
second-line therapy, and best response to first-line therapy.
Advanced NSCLC patients have several first-line chemotherapy
options. Selection of the most appropriate agents should be
discussed with the treating physician.
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